Heart smart: new drug improves blood flow
12 September, 2006 by External Press Release AuthorA new drug has been shown to improve blood flow in diseased arteries, reducing the risk of high blood pressure and heart attacks, a Monash University study has revealed.
Melanoma vaccine trial raises eyebrows
21 July, 2006 by Kate McDonaldA trial of a vaccine for stages II and III melanoma didn't turn out as expected, so the researchers tried it in stage IV patients, causing a few surprises.
Seek and destroy mission for molecular assassin
20 July, 2006 by External Press Release AuthorAn experimental drug designed to seek out and destroy a gene associated with vascular disease is providing effective in early animal trials.
Vaccine researcher critical of CSL, govt approaches to bird flu
02 March, 2006 by Helen SchullerA leading researcher has raised the ire of CSL (ASX:CSL), saying the Melbourne company is "making the wrong vaccine for bird flu."
Monash team in new prostate cancer find
24 February, 2006 by Ruth BeranA team at Monash Institute of Medical Research in Melbourne has grown a human prostate from embryonic stem cells, and hopes the discovery will lead to better understanding of what causes prostate cancer.
CSL posts record profit and upgrade
22 February, 2006 by Ruth BeranMelbourne's CSL (ASX:CSL) today reported a net profit after tax of AUD$176.4 million for the first half of the financial year, up 34 per cent from the previous first half, and has upgraded its full year profit forecast by about 15 per cent to $335 to $350 million.
HealthLinx and Cryptome embark on a future together
21 February, 2006 by Ruth BeranThe first merger of 2006 has created new opportunities in the hot field of theranostics. Ruth Beran talks with its architects about the merged company and its future plans.
Zenyth, MuriGen collaborate on inflammation targets
20 February, 2006 by Ruth BeranZenyth Therapeutics (ASX:ZTL), formerly Amrad, and unlisted Walter and Eliza Hall Institute (WEHI) spinout MuriGen Therapeutics are to co-develop a new class of drugs that target arthritis and other inflammatory diseases.
Oncomere discoveries open new avenues in cancer research
20 February, 2006 by Graeme O'NeillThe junk DNA revolution has thrown up yet another neologism for cancer geneticists to add to their spellcheckers: 'oncomere'.
QIMR scientists to trial malaria vaccine
16 February, 2006 by Ruth BeranScientists at the Queensland Institute of Medical Research (QIMR) are planning to commence a phase I clinical trial in Brisbane for a new malaria vaccine starting late this year or early next year.
Phylogica tech reviewed in journal
13 February, 2006 by Helen SchullerA review of Perth-based Phylogica's (ASX:PYC) Phylomer technology has been published in the February issue of Nature Biotechnology.
BrainZ expands US operations
10 February, 2006 by Helen SchullerAuckland-based BrainZ (ASX:BZI) has established its US clinical support team and headquarters.
DotScan helps join the dots in identifying heart disease
09 February, 2006 by Graeme O'NeillUniversity of Sydney researchers claim to have achieved almost perfect discrimination between two major forms of heart disease from patients' blood samples, using Sydney firm Medsaic's proprietary DotScan technology.
Prana completes Alzheimer's phase I
07 February, 2006 by Helen SchullerMelbourne's Prana Biotechnology (ASX:PBT, Nasdaq:PRAN) has successfully completed a second phase I trial of its lead compound PBT2, under development as a therapy for Alzheimer's disease.
Reshaped Australian healthcare firms hold promise
06 February, 2006 by Sonali PaulMost of Australia's leading healthcare firms are expected to post strong first-half profit growth and provide positive outlook statements as the benefits of takeovers and spin-offs start to filter through, according to analysts.
